生命科学资讯

GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels

Is Illumina’s (ILMN) TruPath Rare Disease Push Reframing Its Clinical Sequencing Investment Narrative? - simplywall.st

Lonza Group AG: Quiet Rally In Swiss Biotech That U.S. Investors Are Missing - AD HOC NEWS

Cardiogenetic testing at scale: the TruGenome Cardiovascular Disease Test and CardioSeq Clinical Trial - Illumina

Agilent Technologies Signals Steady Growth Amid Headwinds - TipRanks

Agilent's Stock Plummets 2.64% as Trading Volume Dips to $0.41B, Ranking 322 in Daily Trading Activity Amid Earnings Miss and Post-Earnings Rally - Bitget

HHS bans Claude AI tool as Trump seeks full government blacklisting of Anthropic

Toward neuroanatomical and cognitive foundations of macaque social tolerance grades

Agilent Technologies Inc. stock underperforms Monday when compared to competitors - MarketWatch

Morgan Stanley cuts Agilent stock price target on valuation multiples - Investing.com

Waters Corporation (WAT) Investor Outlook: Evaluating A Potential 24.63% Upside - DirectorsTalk Interviews

Thermo Fisher (NYSE: TMO) HR chief disposes shares to cover tax liability - Stock Titan

Morgan Stanley cuts Agilent stock price target on valuation multiples - Investing.com

Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan

Two more members added to ACIP ahead of March meeting

Breaking Down 10x Genomics: 11 Analysts Share Their Views - Benzinga

Cullgen ditches reverse merger with Pulmatrix to go with Gyre in $300M buyout

TCE biotech Candid scores Nasdaq listing via reverse merger with rare disease-focused Rallybio

Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline

Thermo Fisher Scientific: Recovery In Life Sciences Solutions (NYSE:TMO) - Seeking Alpha